All News

Choices

Not Still’s – Now What?

d Jack Cush, MD

Your patient doesn't meet criteria for Still’s disease (AOSD or sJIA), now what should you do or consider?

What you do or consider next can be addressed according to the stage of current disease: A) Hospitalized Febrile Disease, or B) Outpatient “Still’s” Disease.

Read Article
RheumNow Podcast square

Social Media Questions (7.29.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and rheumatologist cases from the past week on RheumNow.com. This podcast is brought to you by StillsNow.com - be sure to sign up for our monthly StillsNow email and Monthly StillsNow Podcast.

Read Article
Lungs ILD

Approach to ILD in Myositis Syndromes

d Jack Cush, MD

Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.

Read Article
EMA in Europe has approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who are DMARD-IR or biologic-IR. Based on 3 phase III trials. https://t.co/CbRQGzxJEr https://t.co/SlJNprUay3

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast—Dr.Cush answers your questions! https://t.co/cif6yo0tGi https://t.co/kia5J0OMf6

Links:

Dr. John Cush RheumNow ( View Tweet)
Japanese SLE registry looked at infection risk with Prednisolone (PSL). Among 509 SLE pts (47 yrs); 77% used immunosuppressants & 52 had hospitalized infxns. Signif higher SIE w/ PSL 5.0–7.5 mg (aHR 6.8) & PSL 7.6-15 mg (aHR 7.6) vs 0-2.5 mg/d https://t.co/xZ5Yx4X1uw https://t.co/FSfsTENeUx

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 245 active SLE pts followed x 2 yrs shows low disease activity (LLDAS) achieved in 63%. By multivariate analysis, negative predictors of LLDAS were nephritis, heme involvement & low C3/C4. Early LLDAS predicted future LLDAS-50 https://t.co/IQaDFRtrZy https://t.co/G6MdBOMftX

Links:

Dr. John Cush RheumNow ( View Tweet)
TNR: Still's Now Journal Club - Pivotal Trials in SJIA & AOSD Approved Meds This week's Stills disease Journal Club features expert panelists Drs. Olga Petryna, Daniel Lovell, Hermine Brunner and Jack Cush. https://t.co/2TCtByJg4Q https://t.co/arqQUQJNNC

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatic Causes for Fever of Unknown Origin Fever of unknown origin (FUO) represents a diagnostic challenge to many physicians and while cancer and infectious causes need to be excluded, rheumatic disorders are amongst the most common causes of FUO. https://t.co/JXcp2k6hJ1 https://t.co/5i97sKde8n

Links:

Dr. John Cush RheumNow ( View Tweet)
I had the chance to discuss intrinsic protection from Covid with my friend @ASlavitt https://t.co/dI993XBoXr https://t.co/lidQnzgjJg

Links:

Eric Topol EricTopol ( View Tweet)

Have the trends started to change in awards for more junior people in rheumatology? https://t.co/0UC9BvXfsY

Links:

Rheum Cat rheum_cat ( View Tweet)

15 Powerful Visuals About Psychology & Life 1. https://t.co/ZY6QwhA9bK
Philosophy Pathfinder PhilosophyPath ( View Tweet)
Our commentary on the SELECT-AXIS 2 trial is also available: https://t.co/dkB2h6OeKJ @Spondy_MD https://t.co/GIDXVnhHcz

Links:

Rheum Cat rheum_cat ( View Tweet)

Get insights to difficult to treat rheumatoid arthritis #D2T from the experts👉 This report summarizes what we know and what we still need to know! https://t.co/Qdkcu0Z2sk https://t.co/FW5rvSK1vi

Links:

ARD & RMD Open ARD_BMJ ( View Tweet)
Best Labs for Still’s Disease There is no “test” (blood or other) that is solely diagnostic of Still’s disease, but labs can help make a diagnosis or manage disease, and affirm the safety of drugs in use. What tests should you be ordering? https://t.co/24QSfEEVwG https://t.co/bdrvSBd652

Links:

Dr. John Cush RheumNow ( View Tweet)
The Johns Hopkins Hospital has repeated its top rank among US Rheumatology centers - ranking #1 for the 18th year in a row, according to U.S. News & World Report’s 2022–23 Best Hospitals list. https://t.co/dC5vVEhCrC https://t.co/skXbg1fAve

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 63 Thalassemia pts (50 transfusion dep) w/ 22% α-, 73% β-, 5% α- & β-thal. 23 had inflammatory rheumatic Dz (IRD: RA 9, gout 6, SLE 3, SpA 2). ANA+ in 10% w/o IRD & Transfusion Dep had more + tests for direct Coombs & ANA https://t.co/QW6ecv98F1 https://t.co/GO3xC86hLc

Links:

Dr. John Cush RheumNow ( View Tweet)
TREAT EARLIER Study - Is MTX Intevention in Pre-Clinical RA Warranted? https://t.co/rGcm1DSwJk https://t.co/paBrJVMXdP

Links:

Dr. John Cush RheumNow ( View Tweet)
Belimumab (Benlysta) has been FDA approved for use in pediatric patients with active lupus nephritis who are receiving standard lupus therapy. The approval in kids is for the IV formulation only; SC belimumab is for SLE and LN in adults https://t.co/LCUFDpZM6j https://t.co/R2kA2DbxKy

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of cardiovascular effects of Colchicine: 21 RCTs (15,569 pts shows colchicine was superior to placebo reducing CV events; with lower risk recurrent pericarditis (RR 0.50), MACE (RR 0.67), & AFib recurrence (RR 0.68) https://t.co/oQEF7dmkH8 https://t.co/P7IKeZpcUB

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×